Actively Recruiting
Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration
Led by Fujian Medical University Union Hospital · Updated on 2025-07-02
80
Participants Needed
1
Research Sites
221 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Melasma is a refractory skin disease due to its complex pathogenesis and difficult treatment. Studies have found that human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) could serve as a novel cell-free therapeutic strategy in regenerative and aesthetic medicine. It could potentially treat melasma, but the skin barrier is a challenge. This study aims to explore the safety and efficacy of hUCMSC-Exos in the treatment of melasma and means to promote its percutaneous penetration.
CONDITIONS
Official Title
Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with chloasma who meet clinical diagnostic and efficacy standards and have facial skin lesions
- Willingness to participate in the study with full understanding of its content, risks, and benefits and ability to cooperate
- Agreement to sign informed consent form
- Agreement not to use other cosmetic treatments related to the study during the study period
- Hope that exosomes combined with 1565 nm non-ablative fractional laser, blue aurora plasma, or microneedle can improve facial chloasma
You will not qualify if you...
- Refusal to sign informed consent form
- History of important organ diseases, autoimmune diseases, or immune dysfunction
- Abnormal blood clotting, use of anticoagulants, thrombophilia, or family genetic diseases
- Pregnant or lactating women
- Use of oral contraceptives or hormone replacement therapy during the study or within past 12 months
- Scar constitution
- Active skin infection
- History of severe allergies, hereditary allergies, photosensitivity, or allergic reactions to local anesthetics or lidocaine
- History of post-inflammatory pigmentation
- Previous treatment for chloasma
- Previous chemical peeling, dermabrasion, or skin resurfacing on face
- Participation in other clinical studies
- Other reasons deemed unsuitable by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Affiliated Union Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350001
Actively Recruiting
Research Team
X
xiaosong chen, director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here